NEW YORK, Feb. 18 (GenomeWeb News) - Abbott Laboratories will continue to use Compugen's Genecarta technology for analyzing novel drug targets, Compugen said today.

 

Under the extended agreement, which started in early 2003, Abbott will receive several updates of Compugen's Genecarta database.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.